Evidence map›Paper›PMID 26971679›Full record

ArticleCytotherapy2016

Isolation and trans-differentiation of mesenchymal stromal cells into smooth muscle cells: Utility and applicability for cell-sheet engineering.

Yasuhiro Shudo, Jeffrey E Cohen, Andrew B Goldstone, John W MacArthur, Jay Patel, Bryan B Edwards, Michael S Hopkins, Amanda N Steele, Lydia-Marie Joubert, Shigeru Miyagawa and 2 more

Abstract readEvaluation Study
In one paragraph

Article in Cytotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Yasuhiro ShudoDepartment of Cardiothoracic Surgery, School of Medicine, Stanford University, Stanford, CA, USA; Department of Cardiovascular Surgery, School of Medicine, Osaka University Graduate, Osaka, Japan.
Jeffrey E CohenDepartment of Cardiothoracic Surgery, School of Medicine, Stanford University, Stanford, CA, USA.
Andrew B GoldstoneDepartment of Cardiothoracic Surgery, School of Medicine, Stanford University, Stanford, CA, USA.
John W MacArthurDepartment of Cardiothoracic Surgery, School of Medicine, Stanford University, Stanford, CA, USA.
Jay PatelDepartment of Cardiothoracic Surgery, School of Medicine, Stanford University, Stanford, CA, USA.
Bryan B EdwardsDepartment of Cardiothoracic Surgery, School of Medicine, Stanford University, Stanford, CA, USA.
Michael S HopkinsDepartment of Cardiothoracic Surgery, School of Medicine, Stanford University, Stanford, CA, USA.
Amanda N SteeleDepartment of Cardiothoracic Surgery, School of Medicine, Stanford University, Stanford, CA, USA.
Lydia-Marie JoubertCell Sciences Imaging Facility, Stanford School of Medicine, Stanford University, Stanford, CA, USA.
Shigeru MiyagawaDepartment of Cardiovascular Surgery, School of Medicine, Osaka University Graduate, Osaka, Japan.
Yoshiki SawaDepartment of Cardiovascular Surgery, School of Medicine, Osaka University Graduate, Osaka, Japan.
Y Joseph WooDepartment of Cardiothoracic Surgery, School of Medicine, Stanford University, Stanford, CA, USA. Electronic address: joswoo@stanford.edu.
Stanford University · USOsaka University · JP

Funding

ANGIOGENIC TISSUE ENGINEERING TO LIMIT POST-INFARCTION VENTRICULAR REMODELINGR01HL089315 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI WOO, Y JOSEPH · 2008 to 2023
$6.4M
NHLBI NIH HHS 1R01HL089315-01NHLBI NIH HHS R01 HL089315
6 · The paper itself

Abstract

backgroundBone marrow (BM)-derived mesenchymal stromal cells (MSCs) have shown potential to differentiate into various cell types, including smooth muscle cells (SMCs). The extracellular matrix (ECM) represents an appealing and readily available source of SMCs for use in tissue engineering. In this study, we hypothesized that the ECM could be used to induce MSC differentiation to SMCs for engineered cell-sheet construction.

methodsPrimary MSCs were isolated from the BM of Wistar rats, transferred and cultured on dishes coated with 3 different types of ECM: collagen type IV (Col IV), fibronectin (FN), and laminin (LM). Primary MSCs were also included as a control. The proportions of SMC (a smooth muscle actin [aSMA] and SM22a) and MSC markers were examined with flow cytometry and Western blotting, and cell proliferation rates were also quantified.

resultsBoth FN and LM groups were able to induce differentiation of MSCs toward smooth muscle-like cell types, as evidenced by an increase in the proportion of SMC markers (aSMA; Col IV 42.3 ± 6.9%, FN 65.1 ± 6.5%, LM 59.3 ± 7.0%, Control 39.9 ± 3.1%; P = 0.02, SM22; Col IV 56.0 ± 7.7%, FN 74.2 ± 6.7%, LM 60.4 ± 8.7%, Control 44.9 ± 3.6%) and a decrease in that of MSC markers (CD105: Col IV 64.0 ± 5.2%, FN 57.6 ± 4.0%, LM 60.3 ± 7.0%, Control 85.3 ± 4.2%; P = 0.03). The LM group showed a decrease in overall cell proliferation, whereas FN and Col IV groups remained similar to control MSCs (Col IV, 9.0 ± 2.3%; FN, 9.8 ± 2.5%; LM, 4.3 ± 1.3%; Control, 9.8 ± 2.8%).

conclusionsOur findings indicate that ECM selection can guide differentiation of MSCs into the SMC lineage. Fibronectin preserved cellular proliferative capacity while yielding the highest proportion of differentiated SMCs, suggesting that FN-coated materials may be facilitate smooth muscle tissue engineering.

Indexed as

Cell TransdifferentiationAnimalsCell ProliferationCells, CulturedCell SeparationExtracellular MatrixExtracellular Matrix ProteinsMaleMesenchymal Stem CellsMuscle, SmoothMyocytes, Smooth MuscleRatsRats, WistarTissue EngineeringExtracellular Matrix Proteinscell cultureco-cultureflow cytometryscanning electron microscopy

Identifiers

PMID26971679
PMCPMC5964977
OpenAlexW2295131159

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.